Is the Network planning to assess technologies other than MCDs for cancer screening?
Yes. Although MCDs will be the initial technology assessed by the CSRN through the Vanguard pilot study, the CSRN overall will be agnostic in regard to screening platform. Future CSRN studies will assess a wide variety of cancer screening technologies and strategies.
For the longer-term, how will NCI support active participant follow-up (for example, EHR driven follow-up or follow-up based on NCI's virtual cancer registry)?
Longer-term participant follow-up has not been determined. NCI is interested in exploring options for long-term follow up for screening studies and trials conducted through the CSRN.
Will the MCD assay companies involved in CSRN be required to share their underlying data used to determine a positive test result (such as genomics sequencing data)?
This is to be determined. NCI will establish formal agreements with MCD companies that participate in CSRN studies. The extent to which the companies will provide specific assay data to the CSRN will be negotiated with the companies.
Are additional screening studies permitted as part of the proposals?
Yes. Describing potential additional screening studies is permitted in applications but not required. However, the primary focus of the first four years of the CSRN will be on the Vanguard Study.
Are CSRN trials expected to evaluate only blood tests?
No. Future CSRN trials will not be limited to blood tests. Over time, the CSRN is expected to evaluate a variety of screening technologies and modalities.
Last updated: 01/06/2023